Compare Citigroup Inc. (C) vs GSK plc (GSK) Price & Performance

Citigroup (C) trades at $137.93, up 2.0% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with Q2 2026 EPS beating estimates at $3.06 versus $2.65 expected, revenue growth trending upward from $85.21B in 2025 to $91.4B projected for 2026, and improving net income margins. Recent corporate developments include strategic hires and dividend declarations, while institutional sentiment remains positive with 59% buy ratings.

The outlook for C remains favorable with a consensus price target of $154.38 offering 12% upside potential. Key opportunities include continued earnings growth and efficiency gains from the transformation plan. Risks include volatile cash flows from operations and elevated debt levels, though the current valuation at P/E 14.63 appears reasonable relative to historical performance.

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.